{"id":873531,"date":"2025-08-08T14:19:09","date_gmt":"2025-08-08T18:19:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/"},"modified":"2025-08-08T14:19:09","modified_gmt":"2025-08-08T18:19:09","slug":"deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/","title":{"rendered":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">PHILADELPHIA<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 8, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4484694-1&amp;h=1420731350&amp;u=https%3A%2F%2Fbergermontague.com%2F&amp;a=Berger+Montague+PC\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Berger Montague PC<\/span><\/a><\/u>, a leading <span class=\"xn-location\">Philadelphia<\/span>-based law firm representing investors, announces that a securities class action lawsuit has been filed against <b>Rocket Pharmaceuticals, Inc. <\/b>(<b>NASDAQ: RCKT)<\/b> (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;) on behalf of investors who suffered losses due to <span>alleged<\/span> material misstatements and omissions.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" title=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" alt=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>If you purchased Rocket Pharmaceuticals stock during the period from <b><span class=\"xn-chron\">September 17<\/span>, 202<\/b><b>4\u00a0to <span class=\"xn-chron\">May 26, 2025<\/span><\/b>(the &#8220;Class Period&#8221;), you may be entitled to compensation. The deadline to seek lead plaintiff status is <b><span class=\"xn-chron\">August 11, 2025<\/span><\/b>. <i>To learn your rights, <b><u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4484694-1&amp;h=1123121444&amp;u=https%3A%2F%2Finvestigations.bergermontague.com%2Frocket-pharmaceuticals%2F&amp;a=CLICK+HERE\" target=\"_blank\" rel=\"nofollow\">CLICK HERE<\/a><\/u>.<\/b><\/i><\/p>\n<p>Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, <span class=\"xn-location\">New Jersey<\/span>, specializes in gene therapies for rare and life-threatening diseases.<\/p>\n<p>The lawsuit claims the Company failed to disclose major safety-related updates to its RP-A501 clinical trial, including the use of an immunomodulatory agent, prior to a fatal adverse event and FDA-imposed clinical hold. After the Company publicly confirmed the trial hold and patient death on <span class=\"xn-chron\">May 28, 2025<\/span>, RCKT shares fell sharply dropping from <span class=\"xn-money\">$6.27<\/span> to <span class=\"xn-money\">$2.33<\/span>.<\/p>\n<p>\n        <b>About <span class=\"xn-person\">Berger Montague<\/span><br \/><\/b><br \/>\n        <span class=\"xn-person\">Berger Montague<\/span>, with offices in <span class=\"xn-location\">Philadelphia<\/span>, <span class=\"xn-location\">Minneapolis<\/span>, <span class=\"xn-location\">Delaware<\/span>, <span class=\"xn-location\">Washington, D.C.<\/span>, <span class=\"xn-location\">San Diego<\/span>, <span class=\"xn-location\">San Francisco<\/span>, <span class=\"xn-location\">Chicago<\/span>, <span class=\"xn-location\">Malvern<\/span>, and <span class=\"xn-location\">Toronto<\/span>, has been a pioneer in <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4484694-1&amp;h=1656814369&amp;u=https%3A%2F%2Fbergermontague.com%2Fsecurities%2F&amp;a=securities+class+action+litigation\" target=\"_blank\" rel=\"nofollow\">securities class action litigation<\/a><\/u> since its founding in 1970. <span class=\"xn-person\">Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>For more information or to discuss your rights, please contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Andrew Abramowitz<\/span>, Senior Counsel<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-3015<br \/><a href=\"mailto:aabramowitz@bergermontague.com\" target=\"_blank\" rel=\"nofollow\">aabramowitz@bergermontague.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Caitlin Adorni<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">Berger Montague<\/span><br \/>\n        <br \/>(267) 764-4865<br \/><a href=\"mailto:cadorni@bergermontague.com\" target=\"_blank\" rel=\"nofollow\">cadorni@bergermontague.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC47520&amp;sd=2025-08-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025-302525376.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025-302525376.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Berger Montague<\/span><\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC47520&amp;Transmission_Id=202508081416PR_NEWS_USPR_____DC47520&amp;DateId=20250808\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA , Aug. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;) on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purchased Rocket Pharmaceuticals stock during the period from September 17, 2024\u00a0to May 26, 2025(the &#8220;Class Period&#8221;), you may be entitled to compensation. The deadline to seek lead plaintiff status is August 11, 2025. To learn your rights, CLICK HERE. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-873531","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , Aug. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;) on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purchased Rocket Pharmaceuticals stock during the period from September 17, 2024\u00a0to May 26, 2025(the &#8220;Class Period&#8221;), you may be entitled to compensation. The deadline to seek lead plaintiff status is August 11, 2025. To learn your rights, CLICK HERE. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates &hellip; Continue reading &quot;DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-08T18:19:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025\",\"datePublished\":\"2025-08-08T18:19:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/\"},\"wordCount\":278,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/\",\"name\":\"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-08-08T18:19:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/","og_locale":"en_US","og_type":"article","og_title":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , Aug. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;) on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purchased Rocket Pharmaceuticals stock during the period from September 17, 2024\u00a0to May 26, 2025(the &#8220;Class Period&#8221;), you may be entitled to compensation. The deadline to seek lead plaintiff status is August 11, 2025. To learn your rights, CLICK HERE. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates &hellip; Continue reading \"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-08T18:19:09+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025","datePublished":"2025-08-08T18:19:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/"},"wordCount":278,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/","name":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-08-08T18:19:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-next-week-berger-montague-advises-rocket-pharmaceuticals-nasdaq-rckt-investors-to-contact-the-firm-before-august-11-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=873531"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873531\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=873531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=873531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=873531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}